10月15日，沃森生物盘中上涨2.02%，截至11:04，报11.62元/股，成交1.60亿元，换手率0.89%，总市值 185.84亿元。 截至6月30日，沃森生物股东户数11.73万，较上期增加3.73%；人均流通股13268股，较上期减少 3.88%。2025年1月-6月，沃森生物实现营业收入11.54亿元，同比减少19.47%；归母净利润4316.06万 元，同比减少74.69%。 分红方面，沃森生物A股上市后累计派现4.03亿元。近三年，累计派现4798.05万元。 机构持仓方面，截止2025年6月30日，沃森生物十大流通股东中，易方达创业板ETF（159915）位居第 一大流通股东，持股4027.18万股，相比上期减少106.18万股。招商国证生物医药指数A（161726）位居 第三大流通股东，持股2697.65万股，相比上期减少219.52万股。南方中证500ETF（510500）位居第五 大流通股东，持股2381.22万股，相比上期增加318.93万股。香港中央结算有限公司位居第十大流通股 东，持股1996.71万股，相比上期减少163.00万股。 责任编辑：小浪快报 资金流向方面，主力资金净 ...

Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, is located in Kunming, Yunnan Province. The company specializes in the research, production, and sales of vaccine products [1] - The main revenue composition includes self-developed vaccine products (94.82%), intermediate products (4.67%), other (supplement) (0.26%), and technical services (0.24%) [1] Financial Performance - For the first half of 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47%. The net profit attributable to shareholders was 43.16 million yuan, down 74.69% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [3] Stock Performance - As of September 19, Watson Bio's stock price was 11.95 yuan per share, with a market capitalization of 19.112 billion yuan. The stock has decreased by 0.99% year-to-date and by 3.94% over the last five trading days [1] - The stock experienced a net outflow of 37.44 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 117,300, while the average circulating shares per person decreased by 3.88% to 13,268 shares [2] - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3]